{"DataElement":{"publicId":"4475081","version":"1","preferredName":"Treatment Cohort Study 9343 Code","preferredDefinition":"The code that represents the information pertaining to protocol 9343 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9343_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2497526","version":"1","preferredName":"Treatment Cohort Study","preferredDefinition":"Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"TX_COHORT_STDY","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2416951","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"02DBEE3F-243E-103A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2497524","version":"1","preferredName":"Cohort Study","preferredDefinition":"Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"C15208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FC9E-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"ONEDATA","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FCAF-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"SOKKERL","dateModified":"2017-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4474350","version":"1","preferredName":"9343 Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic._A system of numbered categories for representation of data.","longName":"4474350v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"250","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"H1 DL-1","valueDescription":"H1 DL-1 = Hepatic: Mild (Bilirubin less than or equal to ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 125 mg PO Day 1 & 125 mg PO BID days 2-28; Cycles 2+ Dabrafenib 125 mg PO BID","ValueMeaning":{"publicId":"4647493","version":"1","preferredName":"H1 DL-1 = Hepatic: Mild (Bilirubin less than or equal to ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 125 mg PO Day 1 & 125 mg PO BID days 2-28; Cycles 2+ Dabrafenib 125 mg PO BID","longName":"4647493","preferredDefinition":"H1 DL-1 = Hepatic: Mild (Bilirubin less than or equal to ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 125 mg PO Day 1 & 125 mg PO BID days 2-28; Cycles 2+ Dabrafenib 125 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C645-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C65E-079F-E050-BB89AD4312ED","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H1 DL-2","valueDescription":"H1 DL-2 = Hepatic: Mild (Bilirubin less than or equal to ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 100 mg PO Day 1 & 100 mg PO BID days 2-28; Cycles 2+ Dabrafenib 100 mg PO BID","ValueMeaning":{"publicId":"4647494","version":"1","preferredName":"H1 DL-2 = Hepatic: Mild (Bilirubin less than or equal to ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 100 mg PO Day 1 & 100 mg PO BID days 2-28; Cycles 2+ Dabrafenib 100 mg PO BID","longName":"4647494","preferredDefinition":"H1 DL-2 = Hepatic: Mild (Bilirubin less than or equal to ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 100 mg PO Day 1 & 100 mg PO BID days 2-28; Cycles 2+ Dabrafenib 100 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C668-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C681-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H1 DL-3","valueDescription":"H1 DL-3 = Hepatic: Mild (Bilirubin less than or equal to  ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 75 mg PO Day 1 & 75 mg PO BID days 2-28; Cycles 2+ Dabrafenib 75 mg PO BID","ValueMeaning":{"publicId":"4647495","version":"1","preferredName":"H1 DL-3 = Hepatic: Mild (Bilirubin less than or equal to  ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 75 mg PO Day 1 & 75 mg PO BID days 2-28; Cycles 2+ Dabrafenib 75 mg PO BID","longName":"4647495","preferredDefinition":"H1 DL-3 = Hepatic: Mild (Bilirubin less than or equal to  ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 75 mg PO Day 1 & 75 mg PO BID days 2-28; Cycles 2+ Dabrafenib 75 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C68B-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C6A4-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H1 DL-4","valueDescription":"H1 DL-4 = Hepatic: Mild (Bilirubin less than or equal to ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib: 50 mg PO Day 1 & 50 mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","ValueMeaning":{"publicId":"4647496","version":"1","preferredName":"H1 DL-4 = Hepatic: Mild (Bilirubin less than or equal to ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib: 50 mg PO Day 1 & 50 mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","longName":"4647496","preferredDefinition":"H1 DL-4 = Hepatic: Mild (Bilirubin less than or equal to ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib: 50 mg PO Day 1 & 50 mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C6AE-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C6C7-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H1 DL1","valueDescription":"H1 DL1 = Hepatic: Mild (Bilirubin less than or equal to ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 150 mg PO Day 1 & 150 mg PO BID days 2-28; Cycles 2+ Dabrafenib 150 mg PO BID","ValueMeaning":{"publicId":"4647497","version":"1","preferredName":"H1 DL1 = Hepatic: Mild (Bilirubin less than or equal to ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 150 mg PO Day 1 & 150 mg PO BID days 2-28; Cycles 2+ Dabrafenib 150 mg PO BID","longName":"4647497","preferredDefinition":"H1 DL1 = Hepatic: Mild (Bilirubin less than or equal to ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 150 mg PO Day 1 & 150 mg PO BID days 2-28; Cycles 2+ Dabrafenib 150 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C6D1-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C6EA-079F-E050-BB89AD4312ED","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H2 DL-1","valueDescription":"H2 DL-1=Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN); Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 125mg PO d1 & 125mg PO BID days 2-28; Cycles 2+ Dabrafenib 125mg PO BID","ValueMeaning":{"publicId":"4647498","version":"1","preferredName":"H2 DL-1=Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN); Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 125mg PO d1 & 125mg PO BID days 2-28; Cycles 2+ Dabrafenib 125mg PO BID","longName":"4647498","preferredDefinition":"H2 DL-1 = Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN); Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 125mg PO d1 & 125mg PO BID days 2-28; Cycles 2+ Dabrafenib 125mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C6F4-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C70D-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H2 DL-2","valueDescription":"H2 DL-2=Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN); Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 100mg PO d1 & 100mg PO BID days 2-28; Cycles 2+ Dabrafenib 100mg PO BID","ValueMeaning":{"publicId":"4647499","version":"1","preferredName":"H2 DL-2=Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN); Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 100mg PO d1 & 100mg PO BID days 2-28; Cycles 2+ Dabrafenib 100mg PO BID","longName":"4647499","preferredDefinition":"H2 DL-2 = Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN); Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 100mg PO d1 & 100mg PO BID days 2-28; Cycles 2+ Dabrafenib 100mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C717-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C730-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H2 DL-3","valueDescription":"H2 DL-3 = Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN); Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 75mg PO d1 & 75mg PO BID days 2-28; Cycles 2+ Dabrafenib 75mg PO BID","ValueMeaning":{"publicId":"4647500","version":"1","preferredName":"H2 DL-3 = Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN); Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 75mg PO d1 & 75mg PO BID days 2-28; Cycles 2+ Dabrafenib 75mg PO BID","longName":"4647500","preferredDefinition":"H2 DL-3 = Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN); Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 75mg PO d1 & 75mg PO BID days 2-28; Cycles 2+ Dabrafenib 75mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C73A-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C753-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H2 DL-4","valueDescription":"H2 DL-4 = Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 50mg PO d1 & 50mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","ValueMeaning":{"publicId":"4647501","version":"1","preferredName":"H2 DL-4 = Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 50mg PO d1 & 50mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","longName":"4647501","preferredDefinition":"H2 DL-4 = Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 50mg PO d1 & 50mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C75D-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C776-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H2 DL1","valueDescription":"H2 DL1=Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN); Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 150mg PO d1 & 150mg PO BID days 2-28; Cycles 2+ Dabrafenib 150mg PO BID","ValueMeaning":{"publicId":"4647502","version":"1","preferredName":"H2 DL1=Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN); Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 150mg PO d1 & 150mg PO BID days 2-28; Cycles 2+ Dabrafenib 150mg PO BID","longName":"4647502","preferredDefinition":"H2 DL1 = Hepatic: Moderate (Bili greater than ULN & less than or equal to 3x ULN; AST greater than ULN); Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 150mg PO d1 & 150mg PO BID days 2-28; Cycles 2+ Dabrafenib 150mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C780-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C799-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H3 DL-1","valueDescription":"H3 DL-1=Hepatic:Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min; Cycle 1: Dabrafenib: 125mg PO D1 & 125mg PO BID D 2-28; Cycles 2+ Dabrafenib: 125mg PO BID","ValueMeaning":{"publicId":"4647503","version":"1","preferredName":"H3 DL-1=Hepatic:Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min; Cycle 1: Dabrafenib: 125mg PO D1 & 125mg PO BID D 2-28; Cycles 2+ Dabrafenib: 125mg PO BID","longName":"4647503","preferredDefinition":"H3 DL-1 = Hepatic: Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min; Cycle 1: Dabrafenib: 125mg PO D1 & 125mg PO BID D 2-28; Cycles 2+ Dabrafenib: 125mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C7A3-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C7BC-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H3 DL-2","valueDescription":"H3 DL-2 = Hepatic: Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min);Cycle 1 Dabrafenib 100mg PO D1 & 100mg PO BID D 2-28; Cycles 2+ Dabrafenib 100mg PO BID","ValueMeaning":{"publicId":"4647504","version":"1","preferredName":"H3 DL-2 = Hepatic: Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min);Cycle 1 Dabrafenib 100mg PO D1 & 100mg PO BID D 2-28; Cycles 2+ Dabrafenib 100mg PO BID","longName":"4647504","preferredDefinition":"H3 DL-2 = Hepatic: Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min);Cycle 1 Dabrafenib 100mg PO D1 & 100mg PO BID D 2-28; Cycles 2+ Dabrafenib 100mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C7C6-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C7DF-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H3 DL-3","valueDescription":"H3 DL-3 = Hepatic: Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 75mg PO D1 & 75mg PO BID D 2-28; Cycles 2+ Dabrafenib 75mg PO BID","ValueMeaning":{"publicId":"4647505","version":"1","preferredName":"H3 DL-3 = Hepatic: Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 75mg PO D1 & 75mg PO BID D 2-28; Cycles 2+ Dabrafenib 75mg PO BID","longName":"4647505","preferredDefinition":"H3 DL-3 = Hepatic: Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 75mg PO D1 & 75mg PO BID D 2-28; Cycles 2+ Dabrafenib 75mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C7E9-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C802-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H3 DL-4","valueDescription":"H3 DL-4 = Hepatic: Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib: 50mg PO D1 & 50mg PO BID D 2-28; Cycles 2+ Dabrafenib 50mg PO BID","ValueMeaning":{"publicId":"4647506","version":"1","preferredName":"H3 DL-4 = Hepatic: Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib: 50mg PO D1 & 50mg PO BID D 2-28; Cycles 2+ Dabrafenib 50mg PO BID","longName":"4647506","preferredDefinition":"H3 DL-4 = Hepatic: Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib: 50mg PO D1 & 50mg PO BID D 2-28; Cycles 2+ Dabrafenib 50mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C80C-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C825-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"H3 DL1","valueDescription":"H3 DL1 = Hepatic: Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 150mg PO D1 & 150mg PO BID D 2-28; Cycles 2+ Dabrafenib 150mg PO BID","ValueMeaning":{"publicId":"4647507","version":"1","preferredName":"H3 DL1 = Hepatic: Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 150mg PO D1 & 150mg PO BID D 2-28; Cycles 2+ Dabrafenib 150mg PO BID","longName":"4647507","preferredDefinition":"H3 DL1 = Hepatic: Severe (Bili greater than 3x ULN + up to investigators discretion; AST greater than ULN) Renal: Acceptable (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 150mg PO D1 & 150mg PO BID D 2-28; Cycles 2+ Dabrafenib 150mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C82F-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C848-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"N DL-1","valueDescription":"N DL-1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal (CrCl greater than or equal to  60 mL/min); Cycle 1 Dabrafenib 125 mg PO d1 & 125 mg PO BID days 2-28; Cycles 2+ Dabrafenib: 125 mg PO BID","ValueMeaning":{"publicId":"4647508","version":"1","preferredName":"N DL-1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal (CrCl greater than or equal to  60 mL/min); Cycle 1 Dabrafenib 125 mg PO d1 & 125 mg PO BID days 2-28; Cycles 2+ Dabrafenib: 125 mg PO BID","longName":"4647508","preferredDefinition":"N DL-1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal (CrCl greater than or equal to  60 mL/min); Cycle 1 Dabrafenib 125 mg PO d1 & 125 mg PO BID days 2-28; Cycles 2+ Dabrafenib: 125 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C852-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C86B-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"N DL-2","valueDescription":"N DL-2 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 100 mg PO d1 & 100 mg PO BID days 2-28; Cycles 2+ Dabrafenib 100 mg PO BID","ValueMeaning":{"publicId":"4647509","version":"1","preferredName":"N DL-2 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 100 mg PO d1 & 100 mg PO BID days 2-28; Cycles 2+ Dabrafenib 100 mg PO BID","longName":"4647509","preferredDefinition":"N DL-2 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 100 mg PO d1 & 100 mg PO BID days 2-28; Cycles 2+ Dabrafenib 100 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C875-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C88E-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"N DL-3","valueDescription":"N DL-3 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib: 75 mg PO d1 & 75 mg PO BID  days 2-28; Cycles 2+ Dabrafenib 75 mg PO BID","ValueMeaning":{"publicId":"4647510","version":"1","preferredName":"N DL-3 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib: 75 mg PO d1 & 75 mg PO BID  days 2-28; Cycles 2+ Dabrafenib 75 mg PO BID","longName":"4647510","preferredDefinition":"N DL-3 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib: 75 mg PO d1 & 75 mg PO BID  days 2-28; Cycles 2+ Dabrafenib 75 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C898-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C8B1-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"N DL-4","valueDescription":"N DL-4 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 50 mg PO d1 & 50 mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","ValueMeaning":{"publicId":"4647511","version":"1","preferredName":"N DL-4 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 50 mg PO d1 & 50 mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","longName":"4647511","preferredDefinition":"N DL-4 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 50 mg PO d1 & 50 mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C8BB-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C8D4-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"N DL1","valueDescription":"N DL1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 150 mg PO d1 & 150 mg PO BID days 2-28; Cycles 2+ Dabrafenib 150 mg PO BID","ValueMeaning":{"publicId":"4647512","version":"1","preferredName":"N DL1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 150 mg PO d1 & 150 mg PO BID days 2-28; Cycles 2+ Dabrafenib 150 mg PO BID","longName":"4647512","preferredDefinition":"N DL1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Normal (CrCl greater than or equal to 60 mL/min); Cycle 1 Dabrafenib 150 mg PO d1 & 150 mg PO BID days 2-28; Cycles 2+ Dabrafenib 150 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C8DE-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C8F7-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"R3 DL-1","valueDescription":"R3 DL-1=Hepatic:Normal (Bilirubin less than or equal to ULN;AST less than or equal to ULN) Renal:Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 125 mg PO d1 & 125 mg PO BID days 2-28; Cycles 2+ Dabrafenib 125 mg PO BID","ValueMeaning":{"publicId":"4647513","version":"1","preferredName":"R3 DL-1=Hepatic:Normal (Bilirubin less than or equal to ULN;AST less than or equal to ULN) Renal:Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 125 mg PO d1 & 125 mg PO BID days 2-28; Cycles 2+ Dabrafenib 125 mg PO BID","longName":"4647513","preferredDefinition":"R3 DL-1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 125 mg PO d1 & 125 mg PO BID days 2-28; Cycles 2+ Dabrafenib 125 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C901-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C91A-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"R3 DL-2","valueDescription":"R3 DL-2=Hepatic:Normal (Bilirubin less than or equal to ULN;AST less than or equal to ULN) Renal:Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 100 mg PO d1 & 100 mg PO BID days 2-28; Cycles 2+ Dabrafenib 100 mg PO BID","ValueMeaning":{"publicId":"4647514","version":"1","preferredName":"R3 DL-2=Hepatic:Normal (Bilirubin less than or equal to ULN;AST less than or equal to ULN) Renal:Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 100 mg PO d1 & 100 mg PO BID days 2-28; Cycles 2+ Dabrafenib 100 mg PO BID","longName":"4647514","preferredDefinition":"R3 DL-2 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 100 mg PO d1 & 100 mg PO BID days 2-28; Cycles 2+ Dabrafenib 100 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C924-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C93D-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"R3 DL-3","valueDescription":"R3 DL-3=Hepatic:Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal:Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 75 mg PO d1 & 75 mg PO BID days 2-28; Cycles 2+ Dabrafenib 75 mg PO BID","ValueMeaning":{"publicId":"4647515","version":"1","preferredName":"R3 DL-3=Hepatic:Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal:Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 75 mg PO d1 & 75 mg PO BID days 2-28; Cycles 2+ Dabrafenib 75 mg PO BID","longName":"4647515","preferredDefinition":"R3 DL-3 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 75 mg PO d1 & 75 mg PO BID days 2-28; Cycles 2+ Dabrafenib 75 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C947-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C960-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"R3 DL-4","valueDescription":"R3 DL-4=Hepatic:Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal:Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 50 mg PO d1 & 50 mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","ValueMeaning":{"publicId":"4647516","version":"1","preferredName":"R3 DL-4=Hepatic:Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal:Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 50 mg PO d1 & 50 mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","longName":"4647516","preferredDefinition":"R3 DL-4 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 50 mg PO d1 & 50 mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C96A-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C983-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"R3 DL1","valueDescription":"R3 DL1=Hepatic:Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal:Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 150 mg PO d1 & 150 mg PO BID days 2-28; Cycles 2+ Dabrafenib 150 mg PO BID","ValueMeaning":{"publicId":"4647517","version":"1","preferredName":"R3 DL1=Hepatic:Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal:Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 150 mg PO d1 & 150 mg PO BID days 2-28; Cycles 2+ Dabrafenib 150 mg PO BID","longName":"4647517","preferredDefinition":"R3 DL1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Severe (CrCl greater than or equal to 15 & less than 30 mL/min); Cycle 1 Dabrafenib 150 mg PO d1 & 150 mg PO BID days 2-28; Cycles 2+ Dabrafenib 150 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C98D-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C9A6-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"R4 DL-1","valueDescription":"R4 DL-1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib: 125 mg PO d1 & 125 mg PO BID days 2-28; Cycles 2+ Dabrafenib 125 mg PO BID","ValueMeaning":{"publicId":"4647518","version":"1","preferredName":"R4 DL-1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib: 125 mg PO d1 & 125 mg PO BID days 2-28; Cycles 2+ Dabrafenib 125 mg PO BID","longName":"4647518","preferredDefinition":"R4 DL-1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib: 125 mg PO d1 & 125 mg PO BID days 2-28; Cycles 2+ Dabrafenib 125 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C9B0-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C9C9-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"R4 DL-2","valueDescription":"R4 DL-2 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib 100 mg PO d1 & 100 mg PO BID days 2-28; Cycles 2+ Dabrafenib 100 mg PO BID","ValueMeaning":{"publicId":"4647519","version":"1","preferredName":"R4 DL-2 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib 100 mg PO d1 & 100 mg PO BID days 2-28; Cycles 2+ Dabrafenib 100 mg PO BID","longName":"4647519","preferredDefinition":"R4 DL-2 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib 100 mg PO d1 & 100 mg PO BID days 2-28; Cycles 2+ Dabrafenib 100 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C9D3-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-C9EC-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"R4 DL-3","valueDescription":"R4 DL-3 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib 75 mg PO d1 & 75 mg PO BID days 2-28; Cycles 2+ Dabrafenib 75 mg PO BID","ValueMeaning":{"publicId":"4647520","version":"1","preferredName":"R4 DL-3 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib 75 mg PO d1 & 75 mg PO BID days 2-28; Cycles 2+ Dabrafenib 75 mg PO BID","longName":"4647520","preferredDefinition":"R4 DL-3 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib 75 mg PO d1 & 75 mg PO BID days 2-28; Cycles 2+ Dabrafenib 75 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-C9F6-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-CA0F-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"R4 DL-4","valueDescription":"R4 DL-4 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib: 50 mg PO  d1 & 50 mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","ValueMeaning":{"publicId":"4647521","version":"1","preferredName":"R4 DL-4 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib: 50 mg PO  d1 & 50 mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","longName":"4647521","preferredDefinition":"R4 DL-4 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib: 50 mg PO  d1 & 50 mg PO BID days 2-28; Cycles 2+ Dabrafenib 50 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-CA19-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-CA32-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"},{"value":"R4 DL1","valueDescription":"R4 DL1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib 150 mg PO d1 & 150 mg PO BID days 2-28; Cycles 2+ Dabrafenib 150 mg PO BID","ValueMeaning":{"publicId":"4647522","version":"1","preferredName":"R4 DL1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib 150 mg PO d1 & 150 mg PO BID days 2-28; Cycles 2+ Dabrafenib 150 mg PO BID","longName":"4647522","preferredDefinition":"R4 DL1 = Hepatic: Normal (Bilirubin less than or equal to ULN; AST less than or equal to ULN) Renal: Renal failure (hemodialysis); Cycle 1 Dabrafenib 150 mg PO d1 & 150 mg PO BID days 2-28; Cycles 2+ Dabrafenib 150 mg PO BID","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0B6501A4-CA3C-079F-E050-BB89AD4312ED","latestVersionIndicator":"Yes","beginDate":"2014-12-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0B6501A4-CA55-079F-E050-BB89AD4312ED","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-29","modifiedBy":"ONEDATA","dateModified":"2014-12-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4386398","version":"1","preferredName":"Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic.:A system of numbered categories for representation of data.","longName":"C61512:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE558C16-1C27-C6A8-E040-BB89AD430BEE","latestVersionIndicator":"Yes","beginDate":"2014-07-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-16","modifiedBy":"ONEDATA","dateModified":"2014-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0232063C-657F-5431-E050-BB89AD432D09","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"HARTLEYG","dateModified":"2014-12-29","changeDescription":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Please select the cohort","type":"Preferred Question Text","description":"Please select the cohort","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0240CB81-4BF2-D6E7-E050-BB89AD4330DF","latestVersionIndicator":"Yes","beginDate":"2014-09-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-04","modifiedBy":"HARTLEYG","dateModified":"2014-09-08","changeDescription":"9343_Theradex_ghd_09.04.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}